Valentina Kon

Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis.

Angiotensin in atherosclerosis.

Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice.

Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice.

Proteomic patterns and prediction of glomerulosclerosis and its mechanisms.

Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.

Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.

Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.

Mechanisms for increased cardiovascular disease in chronic kidney dysfunction.

Renal dysfunction potentiates foam cell formation by repressing ABCA1.

Fibrinogen that appears in Bowman's space of proteinuric kidneys in vivo activates podocyte Toll-like receptors 2 and 4 in vitro.

Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.

Scope and mechanisms of obesity-related renal disease.

Atherosclerosis in chronic kidney disease: the role of macrophages.

Glomerular sclerosis is prevented during urinary tract obstruction due to podocyte protection.

Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.

Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity.

Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside.

Protective effects of PPARγ agonist in acute nephrotic syndrome.

Quantitative estimates of the variability of in vivo sonographic measurements of the mouse aorta for studies of abdominal aortic aneurysms and related arterial diseases.

Podocyte injury damages other podocytes.

Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis.

Benzo[a]pyrene potentiates the pathogenesis of abdominal aortic aneurysms in apolipoprotein E knockout mice.

Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.

Maturational regression of glomeruli determines the nephron population in normal mice.

Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.

Importance of high-density lipoprotein quality: evidence from chronic kidney disease.

Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.

Chronic kidney disease induced dysfunction of high density lipoprotein.

Angiotensin-induced abdominal aortic aneurysms in hypercholesterolemic mice: role of serum cholesterol and temporal effects of exposure.

Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Dysfunctional high-density lipoproteins in children with chronic kidney disease.

Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.

Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.

Kidneys: key modulators of high-density lipoprotein levels and function.

Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis.

Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism.

Kidney as modulator and target of "good/bad" HDL.

Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis.

IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD.

Lipoprotein modulation of proteinuric renal injury.

Urinary apolipoprotein AI in children with kidney disease.

Urinary apoAl: novel marker of renal disease?

Inactivation of in Abcg2 lineage-derived cells drives the appearance of polycystic lesions and fibrosis in the adult kidney.

Pro-inflammatory HDL in women with obesity and nonalcoholic steatohepatitis.

Reactive Dicarbonyl Scavenging Effectively Reduces MPO-Mediated Oxidation of HDL and Restores PON1 Activity.

Renal lymphatic vessel dynamics.

Perioperative high density lipoproteins, oxidative stress, and kidney injury after cardiac surgery.

Increased dishevelled associated activator of morphogenesis 2, a new podocyte-associated protein, in diabetic nephropathy.

Kidney injury-mediated disruption of intestinal lymphatics involves dicarbonyl-modified lipoproteins.

Myeloperoxidase-induced modification of HDL by isolevuglandins inhibits paraoxonase-1 activity.

High-Density Lipoproteins in Kidney Disease.

Rice Endosperm Protein Improves the Anti-Inflammatory Effects of High-Density Lipoprotein and Produces Lower Atherosclerotic Lesion Accelerated by the Renal Mass Reduction than Casein in a Mouse Model.

Biotic Supplements in Patients With Chronic Kidney Disease: Meta-Analysis of Randomized Controlled Trials.

Kidney Injury Causes Accumulation of Renal Sodium That Modulates Renal Lymphatic Dynamics.

Podocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker.

Inflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease.

DC ENaC-Dependent Inflammasome Activation Contributes to Salt-Sensitive Hypertension.

Dicarbonyl-modified lipoproteins contribute to proteinuric kidney injury.

Novel Concepts in Nephron Sodium Transport: A Physiological and Clinical Perspective.

Intestinal Lymphatic Dysfunction in Kidney Disease.